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ABSTRACT 
Development of Novel Biomarkers in Cancer: Detection of Circulating miR-
141 as a Potential Prognostic Marker for Prostate Cancer 
 
by 
Jason Cadaoas Gonzales 
Dr. Ronald K. Gary, Examination Committee Chair 
Associate Professor 
University of Nevada, Las Vegas 
 
Prostate cancer (CAP) is the most common epithelial malignancy and the 
second leading cause of cancer deaths in American men.  The identification of 
predictive and prognostic biomarkers in CAP patients is critical for improving 
clinical outcomes.  Although the measurement of prostate-specific antigen (PSA) 
and radiographic studies are clinically approved to predict response to therapy, 
these tests can oftentimes prove to be inadequate in certain patients.  Thus, it is 
important to discover new biomarkers to improve chances of survivability.  We 
and others have shown that longitudinal measurements of circulating tumor cells 
(CTC) and lactate dehydrogenase (LDH) may aid in predicting response to 
therapy.  More recently, levels of microRNA (miRNA) have been implicated in 
disease processes such as cancer.  Specifically, the expression of human 
miRNA miR-141 has been found to be elevated in the plasma of CAP patients.  
In our study, we have measured the levels of miR-141 in 21 CAP patients and 
compared it with other clinical markers (CTC, LDH, and PSA).   We longitudinally 
examined these markers alone and in combination in relationship to the patient’s 
clinical course and response to therapy. Our aim was to determine if miR-141 
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has the potential to be a putative marker for the prognosis of a patient’s response 
to therapy.  
For this retrospective study, plasma from 21 CAP patients were collected at 
different time points corresponding to treatment regimen or follow-up 
appointments.  Levels of miR-141 in plasma were measured using quantitative 
RT-PCR and compared to temporal changes in miR-141, CTC, LDH, and PSA 
levels.  Using PSA as the standard marker in monitoring CAP, correlation 
coefficients were determined for each biomarker’s capability in predicting clinical 
outcomes.  Our results indicate that there is a strong correlation between a 
patient’s clinical characteristics and the plasma levels of miR-141.  With further 
testing, we suggest that miR-141 has the potential to be a marker for the 
prognosis of CAP.  We find that miR-141 is largely concordant with the other 
conventional markers and establish that miR-141 is a relevant biomarker worthy 
of further investigation. 
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CHAPTER 1 
INTRODUCTION 
1.1 Overview of prostate cancer 
In 2006, there was a reported 2.4 million deaths in America with cancer and 
cardiovascular diseases as the two leading causes of these deaths.  More 
specifically, cancer was responsible for 559,000 deaths alone (1).  In 2009, there 
will be 1.4 million newly diagnosed cancers and approximately 562,000 deaths 
attributed to cancer.  It is estimated that in 2010, cancer deaths will surpass heart 
disease in deaths (2). 
For men, the three most commonly diagnosed cancers are prostate, lung and 
gastrointestinal (GI) (3).  In terms of cancer deaths in men, prostate cancer 
(CAP) is one of the leading causes and second only to lung cancer.  
Approximately one in six American men will be diagnosed with CAP in their 
lifetime.  In 2009, there will be an estimated 192,000 new cases whereas another 
one in six, approximately 27,000, will die from the disease.   
Little is known as to what causes CAP.  However, its increased prevalence 
has garnered more interest in discovering the biochemical and physiological 
functions associated with the disease.  Although the pathophysiology is still not 
clearly elucidated, CAP is known to originate in glandular tissue of the prostate.  
A widely considered model has been proposed involving a population of 
precursor cells known as high-grade prostatic intraepithelial neoplasia (PIN).  
These precursor cells are normally isolated within the prostate gland, but can 
eventually become malignant and form tumors (4).  Many genes or gene 
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products have been associated with the development and progression of CAP.  A 
mutation in oncogenes such as c-myc and Ras results in a constitutive activation 
or gain-of-function which results in accelerated growth or facilitates abnormal cell 
division (5-14).  On the other hand, mutations in tumor and metastasis 
suppressor genes such as PTEN, p53 and CD44 results in loss-of-functions (15-
22).   A proposed multistep process of prostate carcinogenesis involves a 
progressive accumulation of these genetic alterations that facilitate the 
transformation from normal prostate tissue to PIN and eventually to full blown 
CAP.  
For CAP patients that have tumors isolated within the capsule of the prostate 
gland, the disease can be cured with therapy such as a prostatectomy or 
radiation therapy.  However, as the disease progresses and becomes metastatic, 
curing it requires more surveillance and therapy.  Metastatic CAP is 
heterogeneously comprised of two types of malignant cells: androgen-dependent 
and androgen-independent (23, 24).  Androgens are steroid hormones that aid in 
the development and maintenance of male characteristics such as testes 
formation and spermatogenesis (25).  In androgen-dependent cells, higher levels 
of androgens can repress the transcription of death-signaling genes necessary 
for apoptosis (26, 27).  Therapies that are targeted to suppress or block the 
production of androgen (androgen ablation therapy) are aimed to allow the 
expression of these death-signaling genes (28, 29).  In contrast, androgen-
independent cells are resistant to any levels of androgens.  These subsets of 
cells are considered castrate-resistant and are therefore insensitive to any type 
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of androgen ablation therapies (30, 31).  The lethality of advanced CAP can 
mainly be attributed to this castrate-resistant form of the disease (32).  
Although significant advances have been made in understanding the 
molecular biology of CAP, this disease continues to be a major health problem.  
Knowing the risk factors and understanding the screening and therapies 
available can help in reducing the burden of this disease.   
  
1.2 Risk factors associated with prostate cancer 
There are several common risk factors associated with CAP: age, ethnicity, 
familial disposition, and diet.  Of these factors, age appears to be very important 
(33).  CAP is usually rare for men under the age of 40, but the incidence 
dramatically increases with age progression, with the most dramatic prevalence 
of CAP occuring between the ages of 61-80 years (34, 35).   
African-American men are more at risk of developing CAP.  The average 
incidence for African-American men in their 70s is approximately 1,600 per every 
100,000.  This is approximately 1.5x the incidence for Caucasians and 2x the 
rate in Asian-Americans (36-38).  It has also been reported that age of onset of 
CAP in African-Americans is earlier than most other ethnicities.   Other studies 
have also discovered that at the time of diagnosis, diagnostics markers, such as 
prostate-specific antigen (PSA) and biopsy scores (Gleason score), and 
progression of disease were elevated or more advanced in African-Americans 
than in any other ethnic group (39, 40).  There is no solid understanding for the 
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disparate figures regarding the risks in African-Americans; however poor access 
to healthcare and education have been suggested (41).   
Studies have shown that men who have first-degree relatives diagnosed with 
CAP have an increased risk for CAP.  For example, a man with at least one other 
immediate family member diagnosed with CAP has twice the risk of being 
diagnosed themselves.  This incidence increases approximately 5- and 10-fold 
when two or more family members are affected (42-47).  Another study has also 
linked prognosis of survival as a potential genetic predisposition whereas a son’s 
survival can be directly correlated to his father’s outcome (48). 
Clearly, age and race seem to strong risk factors when ascertaining one’s 
likelihood of developing CAP.  Although it may seem apparent that one can 
closely predict who will be diagnosed with CAP based on age or genetic 
predispositions, clinical tests must be performed to properly diagnose CAP.  
Unfortunately, the clinical presentation of this disease may be subtle and present 
asymptomatically.  It has been said that most men will die with CAP as opposed 
to dying from it.  An autopsy study analyzing serial sections of the prostate found 
that one-third of men 80 years or younger had CAP whereas in men greater than 
80, two-thirds  were positive for CAP (49).   
 
1.3 Methods of screening 
As with most cancers, early detection is essential for survival.  In fact, the 
five-year survival rate for men diagnosed with cancer presenting localized or 
regional spreading is close to 100 percent.  If the disease has progressed to a 
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more malignant, invasive form, there is a meager 31.9 percent survival rate (33).  
Men who clinically present often have difficulty urinating or have a feeling of 
discomfort in their pelvic region.  Unfortunately, CAP can be present 
asymptomatically and the need of sensitive and specific screening is needed.   
Many tests exist for the screening of CAP.  Digital rectum exams (DRE) and 
determination of prostate specific antigen (PSA) levels are some of the more 
common methods of diagnosis.  Least common tests include prostate biopsies 
and transrectal ultrasonography; however these are not used for primary 
screening due to either cost, availability or their potentially low sensitivity and 
specificity in detecting CAP. 
PSA is a protein produced by prostate epithelial cell and has a half-life of 
approximately 2 days (50).  Total serum PSA has been found to be increased in 
men with CAP and thus has been detected with elevated levels in the serum of 
CAP patients.  The increase in detectable PSA in the serum is due to a disruption 
of the tissue barriers between the prostate gland lumen and the capillary.  
Unfortunately, PSA levels can also be increased in the men exhibiting enlarged 
prostates, also known as benign prostatic hyperplasia (BPH).  Prostatitis, digital 
rectal exams, ejaculation, and prostate biopsies can also lead to an increase of 
PSA in serum (51-56). 
To assess an abnormal PSA level in the serum, a cutoff of 4.0ng/mL has 
been established.  At this level, studies have determined the PSA sensitivity and 
specificity is at an estimated 70 to 80 percent and 60 to 70 percent, respectively 
(57).  Furthermore, the positive predictive value (a measure of the ability to 
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accurately identify CAP in men with elevated PSA levels) of PSA levels between 
4.0 -10ng/mL was determined to be at 30 percent (58-60).  This predictive value 
increases to approximately 64 percent if PSA levels are determined to be greater 
than 10ng/mL (61). 
To improve on the accuracy of PSA’s diagnostic capabilities, it has been 
proposed to use multiple PSA parameters instead of a single PSA measurement.  
A few of these parameters include measuring free, unbound PSA, the change of 
PSA levels over time (PSA velocity), and PSA levels per unit volume of prostate 
(PSA density) (62).  In some instances, men with PSA levels below 4.0ng/mL are 
found to have CAP; therefore some physicians have suggested lowering the 
cutoff to 2.5ng/mL (63-66).  The effort to improve the diagnostic power of PSA 
has yielded multiple potential modifications; however there has been no 
consensus as to which of these modifications can be used to improve diagnosis 
or clinical outcomes.  A major focus in CAP research is determining new 
prognostic serum markers with increased sensitivity and specificity.      
Anatomical examinations such as the digital rectal exam can detect 
abnormalities of the prostate.  These abnormalities include asymmetry, nodules, 
or hardening (induration of the prostate).  A DRE can detect CAP in the lateral 
and posterior aspects of the prostate glands; however, 85 percent of cancers 
occur on the periphery and can only be detected by examination with a finger 
(67).   Most cases of CAP that are diagnosed solely through a DRE present a 
clinically advanced stage of the disease (68).  In fact, multiple studies have 
shown the specificity of the DRE to be at 59 percent, with a sensitivity of 94 
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percent and an overall positive predictive value of 28 percent (69).  The low 
specificity and late disease onset of detection with DRE make it a test best used 
in conjunction with other tests such as PSA screening.  Studies have shown that 
combining the PSA and DRE has greatly improved the rate of CAP detection 
(70).    
For patients with high PSA levels and an abnormal DRE, a prostate biopsy 
can be performed to confirm a CAP diagnosis.  In certain instances, CAP can be 
diagnosed solely through a prostate biopsy.  A biopsy is a procedure where a 
small piece of suspected tissue is extracted from a patient using a needle. The 
resultant tissue is called a biopsy core.  The cores are assessed to determine if 
cells of the tissue are normal or cancerous. Specifically, prostate biopsies are 
performed rectally through the perineum, with the use of a biopsy gun to extract 
cores of tissues (71).  Approximately six needle cores are extracted from the 
base, midzone and apical areas of the prostate gland; however studies suggest 
the assessment of ten needle cores can increase the detection rate (72-75).   
For CAP patients, biopsies of tumors are performed to assess the 
progression of the disease.  Tumor biopsies are performed in the same manner 
as exploratory biopsies and are given numerical grades based on the 
differentiation and structure of the cells present in the tumor.  Cells with normal 
structure and differentiation are given a grade of one, whereas cells with the least 
amount of structure and differentiation are scored a five.  The grades ascertained 
from the biopsy cores are called the Gleason grade (76).  In most instances, 
multiple cell types are exhibited in the core (i.e. a core exhibits cells with a grade 
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of 3 and 4).  In situations where multiple grades exist, the core is given a 
combined score of the two highest-graded cell types exhibited in the core (i.e. a 
score of 7 where cell types of grade 3 and 4 exist).  These combined Gleason 
scores allow physicians to determine the grade or severity of cancer present: 
combined scores of two through four represent a low-grade cancer; scores five 
through seven are considered moderate-grade; scores eight through ten are 
considered high-grade cancers (77, 78). 
Another characteristic of a tumor biopsy that can increase clinical information 
is the extent of the biopsy that is occupied by the tumor.  Whereas a Gleason 
score is a measure of cell differentiation of a tumor,  this estimated tumor volume 
is determined by the amount of biopsy cores that are positive for tumor 
involvement and the percentage of the tumor involvement within each positive 
core.  Together with the level of cell differentiation of a tumor (Gleason score), 
the extent of biopsy cores that are positive for tumors, and the percentage the 
tumor that is occupied within each positive core, a biopsy can provide more 
clinically significant information (79, 80). 
 
1.4 Risks associated with screening 
The value in screening for CAP lies in a test’s ability to reduce the morbidity 
and mortality of this disease.  Currently, only two large randomized trials have 
sought to determine the effectiveness of current screening methods – the 
European Randomized Study of Screening for Prostate Cancer (ERSPC) and the 
United States Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening 
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Trial.  In both studies, men were randomly selected to have interval PSA 
screenings; however in the PLCO study, a DRE supplemented the PSA 
screening (81, 82).   The tests were used to determine which patients should 
receive biopsies and ultimately receive proper treatment.  Collectively, the two 
studies determined that the absolute mortality benefit from screening was 
relatively low.  Meaning, these studies suggest that the current methods and 
frequency of screening for CAP may not help to prevent death versus those who 
do not regularly screen for CAP. 
The low efficacy of the current screening methods may lead to potential harm 
from screening.  Prostate biopsies, for instances, can lead to high anxiety, pain, 
and in rare cases, serious complications that can lead to hospitalization (83, 84).  
Even after a patient undergoes a biopsy, there is potential for a negative biopsy 
result which can lead to increased anxiety due to the high false-negative rates 
(85).  Furthermore, there is an issue of an over diagnosis, whereas the detection 
of conditions through screening may not actually prove to be clinically significant.  
An over diagnosis can subject patients to unnecessary subsequent testing and 
rigorous treatment increasing the chances of harming the individual.    
Although early screening for CAP with PSA and DRE can increase overall 
survivability, patients must be informed of the inherent risks involved with 
screening.  Questions regarding quality of life be must be answered to weigh out 
the benefits of increased screening and treatment.  The absolute risk reduction 
associated with screening is relatively low; therefore men who fall under certain 
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risk factors (i.e. race and family history) or those who are willing to accept the 
risks involved would more likely benefit from screening.  
 
1.5 Treatment of prostate cancer 
There are multiple options to treat CAP.  Physicians most often strategize 
their approaches for treatment based on PSA values, age, and overall health of 
the patient.  A more notable approach to delineating treatment options is based 
on the stage and grade of the disease.  Treatment options for patients with 
clinically localized CAP are approached differently than those who have a more 
advanced progression of the disease (86).  
Treatment option for men with localized CAP include: an active surveillance 
approach, radical prostatectomy and radioactive therapy.  The active surveillance 
approach is an accepted option for patients exhibiting a form of the CAP that has 
a relatively low risk of progression or for patients with a high risk of side effects 
from certain treatments (87). This approach involves the postponement of 
immediate therapy, with treatment administered only if the patient is at increased 
risk or exhibits symptoms of disease progression (88).  This surveillance method 
can drastically reduce the potential for over-treatment or unnecessary risk of 
harm to the patient. 
As cancers progress to a more advanced stage, the disease is more likely to 
become metastatic and affect other tissues or organs.  One of the more common 
organs involved in the metastatic form of CAP is the bone (89).  For men with an 
advanced or recurring form of CAP, a more aggressive therapy must be 
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administered.  Aside from a prostatectomy and localized radiation therapy, 
systemic (whole body) therapy would be a follow up option.  Normal and 
cancerous prostate cells growth are stimulated by androgens; therefore, a 
systemic therapy approach to metastatic CAP would be androgen deprivation 
therapy (ADT).  ADT can be achieved through surgical castration, chemical 
castration or a combination of both.   Unfortunately, a form of CAP exists that is 
androgen-independent which would render ADT useless.  This castrate-resistant 
prostate cancer (CRPC) is most often treated with chemotherapy (90).  However, 
a new form of treatment involving the use of immunotherapy has recently been 
introduced to help treat CRPC (91, 92).  Provenge (Sipuleucel-T) is a form of 
therapeutic cancer vaccine that utilizes a subset of a patient’s leukocytes to 
present an immune-activating antigen.  The immune response activates T-cells 
and is clinically shown to reduce the risk of death by 22% compared to placebo 
(93). 
 
1.6 New and potential biomarkers 
Biological markers, or biomarkers, refer to a measurable biological molecule 
that can reference or indicate any signs of normal or abnormal biological 
processes.  Biomarkers can be used to diagnose and indicate the clinical stage 
of disease (94). Using biomarkers for diagnosing diseases has traditionally been 
focused on detecting enzymes and proteins circulating in the blood, other bodily 
fluids or tissues.  PSA, a serum biomarker, is actively secreted by the prostate 
gland into semen and, in lower instances, other bodily fluids.  Low levels are 
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released into the bloodstream and are a normal occurrence; however injury, 
inflammation, enlargement, or other traumatic events affecting the prostate can 
increase the amount of PSA being released into the bloodstream (95, 96).   
Aside from diagnosing a disease, biomarkers can be powerful tools capable 
of predicting disease outcomes, predicting therapy response or identifying 
patients susceptible to severe side effects.  The use of markers to evaluate 
disease progression is known as a surrogate marker (97).   Surrogate markers 
are biomarkers that can substitute for a clinical endpoint (94).  A clinical endpoint 
is a reference to the distinct overall well-being of a patient undergoing treatment.  
A few of these parameters include how a patient feels, how they are functioning, 
or ultimately if they have survived (94).  Using such markers to predict outcome 
behavior has given rise to the notion of personalized medicine – a course of 
treatment tailored to each patient’s specific tolerance or the potential increase in 
drug efficacy based on  the genetic makeup or biochemical expressions specific 
to each individual. 
The current state of biomarkers has expanded to include the detection of 
intact, circulating cells in the bloodstream.  A growing number of studies have 
focused on detecting circulating tumor cells (CTC) in blood as another potential 
biomarker for disease (98, 99).  The CellSearch™ Circulating Tumor Cell test, 
developed by Veridex, LCC, is currently used to monitor breast and colorectal 
cancers and, in February of 2008, was also approved for its ability to assess CAP 
(100, 101).  Using this test, prognosis for metastatic breast and CAP is defined 
by the number of tumor cells detected in 7.5mL of blood.   
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CTCs are prepared from whole blood in a two-step process:  First, epithelial 
cell adhesion molecule (EpCAM) positive cells are selected using iron-
conjugated EpCAM antibodies.  Enrichment of EpCAM+ cells is achieved using a 
pull-down method utilizing magnets.  Second, CD45 (leukocyte cell marker), 
cytokeratin (marker for keratin-containing intermediate filaments) and nucleic 
acids are stained via allophycocyanin (APC)-labeled antibody, phycoerythrin 
(PE)-labeled antibody and 4',6-diamidino-2-phenylindole (DAPI), respectively.  
The captured CTCs are imaged and scored based on the following criteria:  
cytokeratin+, CD45-, and DAPI+.   Figure 1 summarizes the process to enrich and 
analyze for CTCs. 
Detection of whole, intact cells characterized by CTCs is a clear indication of 
metastatic disease and has proven to be a strong indicator of disease 
progression.  Studies have determined that a CTC count of five or greater as an 
independently predictive parameter of a decreased progression-free survival and 
overall survival (OS).  More specifically, the detection of CTCs has shown to 
correlate well with the progression of metastatic castration-resistant CAP (102).  
Aside with being used as prognostic disease marker, CTCs may be useful in 
validating other biomarker candidates (103, 104).  
The detection of circulating markers found freely in human bodily fluids is not 
limited to proteins or whole cells.  More recently, studies have shown the 
potential of detecting circulating nucleic acids as a marker for diseases.  
Detection of abnormalities in DNA has long been used to diagnose disease; 
however, there are increasing studies focusing on the detection of RNA in 
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determining disease states.  A species of RNA, microRNA (miRNA), has shown 
potential to be a marker for diseases.  These miRNAs are shown, amongst other 
functions, to regulate gene expression. 
 
 
Figure 1: A schematic representation of CTC capture and analysis.  Constituents 
of whole blood for patients with CAP are summarized in panel A.  The whole 
blood is processed in a ferrofluid containing iron-coupled anti-EpCAM antibody to 
immunomagnetically enrich for EpCAM+ cells and remaining cells are stained 
with fluorescent antibodies against CD45 and cytokeratin (Panel B).  Nucleic acid 
is stained and the captured cells are imaged.  CTCs are defined as cytokeratin+ 
and CD45- (panel c; red box), whereas leukocytes are CD45+ and cytokeratin-.  
Cell photographs in panel c are courtesy of Dr. Louis M. Fink and Kristine 
Scarbrough. 
 
Mature miRNAs, the functional form of miRNA, are described as a 22 
nucleotide (nt) species of non-coding RNA.  The biogenesis of mature miRNA is 
preceded by two intermediates: a pri-miRNA and pre-miRNA (Figure 2).  Pri-
miRNA is the initial transcription product of the miRNA-bearing gene and is 
characterized by a stem-loop structure.  The opposing end of the stem loop is 
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cleaved by the Drosha RNase III endonuclease and yields the pre-miRNA.  The 
pre-miRNA is exported into the cytoplasm and the loop end of the pre-miRNA is 
cleaved by the Dicer endonuclease leaving a short, 22nt, double-stranded RNA 
species.  This double-stranded RNA is separated into the single-stranded mature 
miRNA by a helicase.  The regulation of gene expression by miRNA is achieved 
through either translational repression or a site-directed cleavage of the mRNA 
(105, 106). 
 
 
Figure 2: The biogenesis of microRNA.  1) The gene containing the miRNA is 
transcribed.  The transcription product is called pri-miRNA and has a stem-loop 
structure. 2) The pri-miRNA is cleaved at the tail and is now called the pre-
miRNA.  3) The pre-miRNA is exported into the cytoplasm and undergoes more 
modification (cleavage and denaturation) to yield the mature miRNA.  Image 
adapted from Ambion website (107). 
 
 
Since their initial discovery in 1993, the number of miRNA has expanded 
rapidly and the Sanger miRBase sequence database now contains over 900 
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characterized human miRNA (108).  One of the first characterized miRNA, lin-4, 
was found in the roundworm Caenorhabditis elegans (C. elegans) and was 
determined to regulate the expression of lin-14 gene (109).  Today, it is well 
documented that miRNA play a major role in gene regulation and in certain 
disease processes (110, 111).  For example, miRNA expression is known to be 
regulated in cancers such as chronic lymphocytic leukemia, and in lung and 
thyroid cancers (112-114). 
Accurate determination of treatment efficacy is important to increase the 
overall survivability of CAP.  It is therefore beneficial to expand on the current 
repertoire of prognostic serum biomarkers.  Initial efforts to identify a putative 
marker can be expensive and must be validated to prove its prognostic 
capabilities.  Fortunately, current validated markers can be used to compare and 
aid in the validation of the predictive characteristics of a putative prognostic 
marker. 
 
1.7 Purpose of the study 
Discovering novel biomarkers for diagnosing or prognosing diseases such as 
cancer was a major focus of my study.  I have attempted to assess a variety of 
potential biomarkers that would allow for accurate monitoring of disease 
progression in breast and prostate cancers.  My preliminary focus was aimed at 
developing both a protein-based and gene expression assay (through the 
detection of messenger RNA) for the simultaneous detection of SALL4 and BMI1 
proteins in prostate and breast cancer.  Furthermore, access to patient serum 
17 
samples has allowed me to assess the potential for a biomarker assay, currently 
marketed as a cancer biomarker panel that was developed with an emphasis 
towards ovarian cancer, to detect the progression of breast cancer. 
A major hurdle of clinical and translational studies can be the availability and 
integrity of patient samples.  The progression of my biomarker studies was 
complicated by such challenges.  For instance, a change in samples 
procurement policies has impeded our access to more patient samples and an 
issue of sample degradation in banked samples complicated certain aspects of 
my study.  We were fortunate, however, to have enough samples to focus 
attention to the detection of circulating miRNA in CAP.  The focus of my thesis 
will be this on this miRNA study in prostate cancer; however I present a 
preliminary assessment of a cancer biomarker panel and its potential utility in 
detecting breast cancer can be found in appendix figure A1.  Furthermore, our 
preliminary results of the gene expression assay for the detection of SALL4 and 
BMI1 in breast cancer can be found in appendix figure A2.  A table that 
summarizes all experiments or attempts to detect novel biomarkers in prostate 
and breast cancer can be found in appendix table A1. 
CAP is one of the leading causes of cancer deaths in American men.  
Physical and anatomical examinations such as the digital rectal and prostate 
biopsies are performed to detect and diagnose CAP.  Furthermore, detection of 
biomarkers has also been used to diagnose and monitor CAP.  Examples of 
these biomarkers include the prostate specific antigen (PSA) and lactate 
dehydrogenase (LDH).  Currently, more emphasis has been placed in 
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discovering new diagnostic and monitoring tools for the early detection and 
accurate prognostication of this disease.  Accurately monitoring the disease 
during a treatment regimen will allow physicians to determine the efficacy of the 
current treatment and can allow for punctual changes in treatment regimen.  Just 
as PSA can aid in the diagnosis of CAP, PSA is also used as a predictive marker 
for monitoring disease.   
Although tests such as the prostate biopsies and detection of PSA have been 
used confidently for many years, each test has known specificity and sensitivity 
drawbacks.  It is for those reasons that physicians often use tests in conjunction 
with one-another, rather than individually, to diagnose or monitor the progression 
of CAP.  Furthermore, tests such as the prostate biopsy are highly invasive and 
can lead to painful side effects.  Digital rectal exams, although not invasive, can 
cause pain and stress to patients.   An ideal test would have increased specificity 
and sensitivity than those of current tests and would ideally be less invasive and 
painful to the patients.  Biomarkers are thought to be ideal in that these are 
normally detected from a patient’s blood - meaning it is non-invasive and pain 
would only be measured from a patient’s tolerance to needle-stick procedures.  
A recent study by Mitchell et al. discovered that human miR-141 was stable 
and detectable in plasma of CAP patients (115).  miR-141 is encoded on 
chromosome 12 and is a part of the miR-200 family known to regulate the 
transition from epithelial to mesenchymal tissue.  This morphological change in 
cells reduces intercellular contacts and is a characteristic of metastasis (116-
118).  Nevertheless, the exact role of miR-141 in CAP is currently unclear.  In this 
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study, we quantitate the circulating levels of miR-141 in plasma of castration-
resistant and hormone-sensitive metastatic CAP patients undergoing treatment 
and retrospectively compared it to levels of PSA, CTC and LDH - conventional 
biomarkers used to monitor CAP. Temporal changes in copy number of 
circulating miR-141 were compared to the other markers and it was determined if 
miR-141 concomitantly correlated with values of the conventional markers 
determined at the same time points.   
The purpose of this study is to demonstrate the possible benefits of using 
miR-141 as a biomarker through its correlation with treatment response.  We 
hypothesize that values of miR-141 detected in patient plasma are concordant 
with values of PSA and clinical assessments and can prove to be a marker for 
the prognosis of CAP.   
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CHAPTER 2 
METHODS 
2.1 Chemicals, reagents and equipment 
Trizol LS Reagent was obtained from Invitrogen (Carlsbad, CA).  
Diethylpyrocarbonate (DEPC)-treated water was obtained from EMD Chemicals 
(Gibbstown, NJ).  99.5% A.C.S. grade, 200 proof ethanol was obtained from 
Acros Organics (Morris Plains, NJ).  PCR reaction tubes were obtained from 
VWR (West Chester, PA).  Molecular biology certified chloroform and 
isopropanol was obtained from IBI Scientific (Peosta, IA).  Ribooligonucleotides 
for the generation of standard curves were obtained from Integrated DNA 
Technologies (Coralville, Iowa).   7500 Fast Real Time PCR Thermocycler, 
reverse transcription kits for the cDNA amplification of Caenorhabditis elegans (c. 
elegans) miRNA cel-miR39 and Homo sapien miRNA hsa-miR-141, TaqMan 
MicroRNA Assays, 96-well Thermocylcing Plate, and MicroAmp Optical Adhesive 
PCR sealing film were obtained from Applied Biosytems (Foster City, CA).  
miRVana miRNA extraction kit and THE RNA Storage solution were obtained 
from Ambion (Austin, TX).  Sterilization of equipment and work surfaces from 
RNase and DNA contamination was performed with RNase Away and DNA Away 
obtained from Molecular BioProducts (San Diego, CA).   
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2.2 Biological sample collection 
All patients and control subjects were consented by staff of the Nevada 
Cancer Institute and all biological samples pertaining to this study were stored on 
site in the institute’s biorepository.  Control samples were collected from 
consenting volunteers that, to the best of their knowledge, were known to be 
cancer-free.  Biological samples of control subjects were kept anonymous and 
did not have any clinical tests performed on them (i.e. PSA or CTC testing).  CAP 
patients used in this study were patients of Nevada Cancer Institute. In most 
instances, biological samples were collected in conjunction with their treatment or 
follow up visits. 
For this retrospective study, CAP samples were chosen by one physician to 
reflect a range of clinical biomarker changes (rising or declining PSA and CTC 
values) against which miR-141 could be compared. These samples were chosen 
prior to the determination of miR-141 values. All samples were collected and 
processed under approved Institutional Review Board (IRB) protocols. These 
samples were chosen independent of the patient’s clinical assessment, where 
one’s clinical assessment is the diagnosis and prognosis of the patient based on 
medical history, performance and clinical lab tests.   Each patient’s clinical 
assessment was determined by one consulting oncologist and was based on 
overall chart review and reflects clinical and/or radiographic disease progression. 
Each assessment was made independently and in a blind fashion in respects to 
all biomarker values.  
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Blood was collected in K2-EDTA tubes from CAP patients with ages ranging 
from 60-77 at the time of first blood draw. Each tube was centrifuged at 3,300 
rpm for 10 minutes to separate the peripheral blood platelet pool. Plasma was 
aspirated from the tubes, aliquotted into cryogenic tubes and stored at -80°C until 
analysis. A separate sample of blood was used to run PSA, LDH and CTC 
analysis on these CAP patients. The PSA was run on serum samples using the 
Bayer-Centaur methodology, CTC analysis was done according to Veridex’s 
standard operating protocol, and LDH was determined using the Olympus LD 
procedure.  All approved clinical testing were performed by licensed clinical 
laboratory staff.  Each CAP patient also had subsequent blood draws at different 
time points coinciding with their schedule of therapy, thus allowing a longitudinal 
analysis for each biomarker.  All control subjects were closely age-matched and 
were subjected to one blood draw only; therefore control samples do not have 
longitudinal analyses. 
 
2.3 Determination of miR-141 expression 
MicroRNA was extracted from plasma using the mirVana PARIS kit protocol 
(Ambion) (15). A modification of the extraction protocol was performed by 
including a second organic extraction with phenol:chloroform (Ambion) of total 
RNA prior to final purification of miRNA.   
To normalize the reactions, we utilized an exogenous miRNA species not 
detected in human plasma, cel-miR-39 - an miRNA expressed exclusively in 
Caenorhabditis elegans (c. elegans).  For most expression assays, normalization 
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is achieved through the detection of endogenous controls.  Endogenous controls 
are most often associated with the detection of constitutively expressed proteins 
such as the housekeeping genes β-actin and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH); however the normalization of studies utilizing miRNA 
has been complicated by the absence or inability to detect a true endogenous 
species of miRNA.  Furthermore, since the mechanism of circulating miRNA in 
prostate cancer has not been deduced, nor has there been any true 
establishment of circulating endogenous miRNA,  the nature of our study has 
further complicated the establishment of an endogenous control.   Therefore, the 
use of an exogenous control was necessary.  500pg of synthesized cel-miR-39  
ribo-oligonucleotide was spiked into each plasma sample following an initial 
denaturing step and served as our normalization, positive and loading miRNA 
control (IDT; cel-miR-39 sequence 5’-rUCACCGGGUGUAAAUCAGCUUG-3’).  
The resulting miRNA was eluted using THE RNA storage solution (Ambion) and 
either immediately subjected to a reverse transcription reaction or stored at - 
80°C.   
In order to determine absolute quantitation of miRNA, standard curves were 
generated for both cel-miR-39 and miR-141 using synthesized ribo-
oligonucleotides in separate reaction vessels (IDT; miR-141 sequence 5’-
rUAACACUGUCUGGUAAAGAUGG-3’). A 6-point standard curve was created 
starting with an RNA concentration of 100pg/μL with subsequent 10-fold dilutions 
with DEPC-treated water to a final concentration of 1.00fg/μL.  Reverse 
transcription of miR-141 and cel-miR-39 from extracted samples and standard 
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curves was achieved using a TaqMan miRNA Reverse Transcription Kit (Applied 
Biosystems) with specific stem-loop primers for each miRNA to be assessed 
(Figure 3; Applied Biosystems). Reverse transcription reactions were incubated 
in a PTC-200 thermocycler (MJ Research) under the following conditions: 16°C 
for 30 minutes, 42°C for 30 min, 85°C for 5 min, and then held at 4°C (23). 
 
 
Figure 3:  Principle of reverse transcription to produce cDNA template from 
miRNA using a looped primer.  The unique stem-loop structure of the primer 
allowed for high specificity of binding of miRNA species only.   
 
Quantitative RT- PCR for each sample and standard curve was performed in 
triplicate in a reaction mixture of TaqMan miRNA target-specific probe (Applied 
Biosystems) and 2x Universal PCR Master Mix (Applied Biosystems) in a final 
volume of 5uL. PCR reactions were performed in a 96-well thermocycling plate 
sealed with optically-clear sealing film and were run under the following 
conditions in 7500 Fast PCR Thermocycler (Applied Biosystems): non-fast 
conditions with an initial enzyme activation of 95°C for 10 min, followed by 40 
cycles of 95°C for 15 seconds, 60°C for 1 minutes where data was collected at 
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the 60°C step.  Although TaqMan signals were recorded at the last step of each 
cycle, the data were analyzed at the final cycle of the reaction (last step of cycle 
40).   
Our determination of miR-141 copy number for each sample was an endpoint 
analysis and the signal was interpreted into the amount of miR-141 determined 
on each sample based on a linear regression equation extrapolated from our 
standard curve.  Figure 4 is a representative standard curve and extrapolated 
equation observed throughout the study.  Normalization of the reaction was 
based on the cycle threshold values from the spiked endogenous control (cel-
miR-39). Calculation of miR-141 copy number was as previously described (18). 
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Figure 4:  A representative standard curve to determine miR-141 concentration.   
Each standard curve represents the correlation of input RNA vs. expected. A 
linear regression equation was used to extrapolate the miR-141 concentration for 
each sample in the study.  PCR efficiency can also be determined from the slope 
obtained in each reaction. 
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Aside from an extrapolated input miRNA concentration, we are also able to 
determine the efficiency of our qRT-PCR from our standard curves.  In theory, a 
reaction efficiency of 100% should yield a PCR reaction where products are 
doubling after each subsequent cycle.  Using the slope obtained from the 
standard curve, a measure of exponential amplification and PCR efficiency can 
be determined.  A slope of -3.3 yields an exponential amplification of 2 
(conferring a doubling of PCR product from previous cycles) and an efficiency of 
100%.  Throughout the study, we experienced an average slope of -3.42 that 
yielded an average exponential amplification of 1.96 and an average PCR 
efficiency of 96.1%. 
 
2.4 Statistical methods 
To assess the statistical relevance of the temporal changes of biomarker 
values, each data point was transformed to a log10 value.   The transformed data 
for each interval were used as data points on a regression plot yielding a slope 
corresponding to the temporal rate of biomarker change.  Slopes were calculated 
for each biomarker and for each patient separately and were used as the 
outcome variables for the analyses described below.  All analyses were 
conducted on two separate cohorts:  cohort 1 included patients with exactly two 
blood samples and cohort 2 included patients with 3 or more blood samples.  For 
all statistical analyses, we chose PSA as the predictor because it is considered 
the gold standard biomarker used to assess response to therapy of CAP. 
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1. Analysis of variance for each cohort. 
a. Group 1 was defined as all patients with increasing PSA 
(positive PSA slope).  Group 2 was defined as all patients with 
decreasing PSA (negative slope). 
b. Analysis of variance was conducted for the 4 slopes (PSA, LDH, 
CTC’s, and miRNA) as a function of Group as defined above.  
PSA slope ANOVA is biased because the PSA slopes defined 
the groups.  Results for PSA are still provided for descriptive 
purposes. 
 
2. Correlation analysis.  Pearson correlation coefficients were calculated 
for the 4 slopes:  PSA vs LDH, PSA vs CTC, PSA vs miR-141, LDH vs 
CTC, LDH vs miR-141, and CTC vs miR-141. 
 
3. Binary Classification analysis 
a. Binary variables were calculated for each of the 4 biomarker 
slopes.  A “1” was assigned if the slope was positive.  A “0” was 
assigned if the slope was negative. 
b. Sensitivity and specificity were calculated for 3 pairs of 
biomarkers using PSA as the standard. 
c. Sensitivity and specificity for other combinations were also 
calculated.  
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CHAPTER 3 
RESULTS 
The miR-141 values of the control samples are summarized in table 1 and 
observed value ranges are given in table 2.  The clinical assessments and 
biomarker values for each patient in this study are summarized in table 3.  For 
clarification of clinical assessments, patients deemed “regressing” is a patient 
that is clinically performing better, whereas a “progressing” patient has clinically 
gotten worse.  The values of the clinical markers were not used to assess each 
patient as this would confound the analysis; rather the clinical assessments were 
based on the following weight-bearing percentages in determining the 
assessment:  radiographic progression accounted for 50% of the assessment, 
performance status had a 30% weight, progression of pain at 15%, the need to 
change therapies was weighed at 5%, and other systemic symptoms such as 
anorexia or fatigue had <1% weight. 
To assess the ability of miR-141 to prognosticate CAP, we observed two 
characteristics in regards to changes in miR-141 compared to the other clinical 
markers:  1) we sought to determine if temporal changes of miR-141 values 
would be concordant with the changes in other markers and its potential to 
correlate with clinical assessments and 2) the statistical relevance in which miR-
141 can accurately and precisely correlate and classify a patient against the 
standard markers.  When analyzing the results, biomarker data is separated into 
two cohorts: 1) patients providing only two data points (one interval) and 2) 
patients that had three data points to compare (two intervals).  Each data point 
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corresponds to separate dates of sample draws and biomarker determination.  
The time lapsed between each data point differed for each patient and any 
matching intervals were strictly coincidental.    
 
3.1 Raw temporal changes of miR-141 values 
Figure 5 demonstrates the raw fold-change in each biomarker between the 
interval for each patient in cohort 1 (n=8 patients).  Figure 6 demonstrates the 
same fold changes in the two intervals for patients in cohort 2 (n=13 patients).  
The significance of the raw biomarker change is defined by the ability of miR-141 
value to change in concordance with the other markers in either a positive or 
negative manner.  In doing so, we can estimate the potential for miR-141 to 
predict clinical progression. 
Of the eight patients in cohort 1, 6/8 (75%) patients had all biomarkers 
changes in concordance with one another.  Meaning, fold changes in miR-141, 
PSA and CTC either increased or decreased in the same direction during the 
time intervals.  For patients 7 and 14 (25% of cohort population), only two of the 
three biomarkers were concordant with one another.  Since PSA is used as a 
standard assessment tool in progression of this disease, an important 
observation can be made for patient 7: as PSA went down so did his miR-141 
value with an overall clinical assessment of regression.  Whereas in patient 14, a 
clinically progressing patient, miR-141 and CTC values both decreased, with a 
net increase in PSA.  It is important to note, however, that markers changes 
observed in this patient may reflect the emergence of a second metastatic 
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neoplasm (pancreas cancer) during the course of treatment of the metastatic 
CAP. However an autopsy was not done to confirm the presence of two 
malignancies.       
For patients in cohort 2, two intervals were observed.  For five patients 
(patients 6, 5, 8, 17, and 21), all biomarkers were concordant with one another 
during both intervals (38% of cohort).  Two patients (patients 1 and 12) had the 
biomarkers concordant in only the first interval (15% of cohort).  Four of the 
patients (patients 9, 15, 18, and 20) had observed concordant biomarkers in the 
second interval only (30% of cohort).  Finally, two patients (patients 16 and 19) 
did not observe any three marker concordance in either one of the two intervals 
(15%).  Interestingly, of all interval data points that were observed (between both 
cohorts), only one patient had a miR-141 change not be in concordant with 
another biomarker – patient 16.  During interval 1 for this patient, PSA and CTC 
changes were observed to be concordant with each other; specifically, miR-141 
value decreased where PSA and CTC increased.  Clinically, this patient had a 
slowly progressing disease during that interval and the PSA and CTC values 
reflected that.  During this patient’s second interval, the disease rapidly 
progressed, but PSA had a net decrease, where both miR-141 and CTC 
increased.    
Table 4 illustrates the degree of concordance each biomarker had with each 
patient’s clinical assessment.  Keeping in mind that the true clinical assessment 
was ascertained independent of the biomarkers, this assessment of biomarker 
concordance is based on the biomarker interval change and the actual clinical 
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assessment.  Conventional logic deems a clinically progressing disease should 
be associated with an increase of a biomarker and vice versa for a clinically 
regressing disease.  For this assessment, each biomarker was given a “+” if the 
change in marker was concordant with the clinical assessment and given a “-“ if it 
was not; meaning if the clinical assessment was deemed progressive, each 
biomarker should illustrate net increase and scored with a “+”.   
The first draw for each patient was labeled as baseline (designated “b”) and 
therefore a concordance score could not be assessed.  A total of 34 intervals 
were assessed in the study (combined all patients).  For PSA, 29/34 (85%) 
intervals were concordant with the clinical assessment whereas the other 
markers had 27/34 (79%), 25/34 (74%) and 24/34 (71%) for CTC, miR-141 and 
LDH clinical concordance respectively.   
 
3.2 Statistical analysis 
One-way variance of analysis (ANOVA) was performed to determine if there 
was a significant difference between the two groups (positive versus negative 
slope), in their respective marker of study.  This analysis would give us an initial 
indication whether any of the markers could differentiate a regression or 
progression prognosis based on marker values alone.  Tables 5 (cohort 1) and 6 
(cohort 2) provide the p values of both cohorts for each group compared to the 
tested biomarkers.  In cohort 1, we observed p<0.001 for PSA values between 
the two groups.  LDH, CTC had values of p=0.172 and p=0.154, respectively and 
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miR-141 had p=0.007.  In cohort 2, the p-values were p<0.001, p=0.277, p=0.007 
and p=0.024 for PSA, LDH, CTC, and miR-141, respectively.   
To determine the predictive relationships that each biomarker has with one 
another, Pearson correlation coefficients were determined and summarized in 
tables 7 and 8 for cohort 1 and 2, respectively.  As correlation coefficients gets 
closer to 1.00, the tighter the relationships two biomarkers have with one another 
and can, in theory, predict the same degree of change. Correlation coefficients 
for cohort 1 for miR-141 versus PSA was R=0.94 (p<0.001), miR-141 versus 
CTC was R=0.65 (p=0.082), and miR-141 versus LDH was R=0.85 (p=0.008).  
For cohort 2, miR-141 versus PSA was R=0.63 (p=0.021), miR-141 versus CTC 
was R=0.79 (p=0.001), and miR-141 versus LDH was R=0.67 (p=0.013). 
A binary classification analysis, although similar to a correlation analysis, was 
performed to indicate the sensitivity and specificity of a marker in relation to a 
standard.  For a correlation analysis, the outcome variables (slope) was plotted 
to determine the correlation, a binary classification study differs in that each 
slope was assigned binary values based on its regression: either positive or 
negative.  A positive slope was assigned a value of “1” whereas a negative slope 
was assigned a value of “0.”  LDH, CTC and miR-141 were subjected as test 
outcomes for the classification analysis comparing it individually against PSA, 
LDH and CTC values as gold standards.  Classification of biomarkers against 
miR-141 as a standard was not performed as it is not a conventional marker.  
Tables 9 and 10 summarize the classification analysis for cohort 1 and cohort 2, 
respectively. 
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Since a positive slope is a true indicator of a disease that is progressing (a 
marker values that has increased during time point), the percentage of people 
who have a positive slope for a tested marker correctly identified as having a 
positive slope of the standard is an indicator of a marker’s sensitivity.  The 
specificity of a marker is a measure of the proportion of the patients that tested 
with a decline of a test marker (negative slope) with a decline of the standard 
marker. An overall correct classification was determined by samples that 
correctly identified sensitivity and specificity against the whole cohort.   
Testing miR-141 against PSA as the standard yielded a sensitivity of 75%, 
specificity of 100% and a correct classification of 87.5% in cohort 1.  For cohort 
2, the same analysis yielded a value of 75%, 80% and 76.9% for sensitivity, 
specificity and correct classification, respectively.  Performing the same analysis 
on CTC with PSA as the standard measured a 75% of all classifications in cohort 
1 and a 87.5% sensitivity, 100% specificity and 92.3% overall performance in 
cohort 2.  In this classification analysis, miR-141 values outperformed the CTC 
test in its capability to predict a PSA classification for patients with 1 interval, 
whereas with multiple intervals, CTC performed better.  Interestingly, LDH did not 
perform any better than other two markers in predicting a PSA response.  Testing 
miR-141 to predict CTC had a sensitivity, specificity and total classification 
percentages of 75.0%, 100% and 87.5%, respectively for cohort 1 and 85.7%, 
83.3% and 84.6%, respectively for cohort 2. 
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Table 1: miR-141 values of control samples 
Control 
Sample  
miR-141 Value* 
1 1997 
2 1514 
3 263 
4 159 
5 54.0 
6 67.6 
7 115 
8 82.9 
9 3.63 
10 1.63 
* = Copy number/8.35µL 
 
Table 2: Ranges of miR-141 values observed with controls 
miR-141 Value 
Range* 
# Samples in 
Range 
1-10 2 
11-100 3 
101-300 3 
301-1000 0 
1001-3000 2 
* = Copy number/8.35µL 
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Table 3: Patient biomarker values and clinical assessment 
Patient  Draw # 
CTC 
Value*  
PSA 
Value
†
  
LDH 
Value
 ‡
  
miR-141 
Value
§
 
Clinical Assessment 
1 
1 2 90.4 134 29.8 
Interval 1: Progressing rapidly (t = 2 months) 
Interval 2: Regressing slowly (t= 2 months) 
2 40 314.1 1246 135.6 
3 56 238.2 159 760 
2 
1 3 4.5 194 595 
Interval 1: Progressing  slowly (t = 13 months) 
2 401 9.6 282 5165 
3 
1 201 71.8 328 1679 Interval 1: Progressing rapidly during interval. Patient died  
4 days after draw 2 with liver metastases (t = 3 months) 2 356 173.5 2729 18851 
4 
1 0 0.2 311 338 
Interval 1: Progressing  slowly (t = 11 months) 
2 9 2.6 219 1479 
5 
1 0 85.8 143 142 
Interval 1: Progressing slowly (t = 4 months) 
Interval 2: Stable on treatment (t = 21 days) 
2 4 152.4 157 227 
3 9 173 168 389 
6 
1 3 21.5 205 95.9 
Interval 1: Progressing rapidly (t = 2.5 months) 
Interval 2: Progressing slowly (t= 2.5 months) 
2 101 93.0 253.0 1025 
3 206 143.2 291.0 1370 
**4 326 119.0 141.0 4650 
7 
1 0 74.3 155 3337 Interval 1: Progressing  slowly during interval (t = 4 
months) 2 7 9.2 121 589 
8 
1 65 288.8 229 950 
Interval 1: Net slow regrssion (t = 3 months) 
Interval 2: Regressing rapidly (t= 20 days) 
2 1 168.0 155.0 99.8 
3 0 69.7 174.0 36.7 
9 
1 72 57.5 212 475 
Interval 1: Progressing slowly (t = 5 months) 
Interval 2: Regressing slowly (t= 7 months) 
2 12 118.0 262.0 697 
3 1 15.6 N/A 182 
10 
1 41 14.3 234 295 Interval 1: Regressing  slowly during interval (t = 4 
months) 2 0 <0.1 159 24.3 
11 
1 113 259.1 183 9454 Interval 1: Regressing  slowly during interval (t = 2 
months) 2 0 73.1 156 2559 
12 
1 145 2.3 161 1067 
Interval 1: Progressing slowly (t = 2 months) 
Interval 2: Regressing slowly (t= 4 months) 
2 13 1 151 219 
3 0 2.7 132 201 
13 
1 1295 71.8 352 856 Interval 1: Regressing rapidly during interval (t = 6 
months) 2 1 0.2 278 23.4 
14 
1 67 138.1 242 790 
Interval 1: Progressing rapidly (t = 4.5 months) 
2 16 172.5 339 622 
15 
1 3 6.1 225 256 
Interval 1: Regressing slowly (t = 7 days) 
Interval 2: Net slow progression (t= 2.5 months) 
2 5 4.9 324 258 
3 26 17.2 294 1615 
16 
1 28 247 188 795 
Interval 1: Progressing slowly (t = 5.5 months) 
Interval 2: Net slow progression (t= 2.5 months) 
2 30 1184 168 349 
3 273 858 N/A 674 
17 
1 0 4 194 119 
Interval 1: Progressing slowly (t = 3.5 months) 
Interval 2: Rapid progression (t= 3 months) 
2 2 26.3 200 642 
3 17 238 219 1737 
18 
1 0 4.8 147 138 
Interval 1: Progressing slowly (t = 7 months) 
Interval 2: Slow progression (t= 1 month) 
2 3 2.4 170 123 
3 29 18.2 120 427 
19 
1 95 44.7 95 63.0 
Interval 1: Regressing slowly (t = 2 months) 
Interval 2: Slow regression (t= 2 months) 
2 2 6.1 87 64.1 
3 0 3.6 74 94.34 
20 
1 9 1.6 215 1152 
Interval 1: Net slow progression (t = 4.5 months) 
Interval 2: Slow regression (t= 3 months) 
2 7 6.4 290 1323 
3 0 0.3 192 310 
21 
1 8 593.2 340 2053 
Interval 1: Slow regression (t = 2 months) 
Interval 2: Net Slow regression (t= 10.5 months) 
2 2 51.4 265 1923 
3 0 0.2 258 271 
Interval 1= time period between draw 1 and draw 2,  Interval 2 = time period between draw 2 and draw 3 
t = time, * = Number of CTC/7.5mL of blood, † = ng/mL, ‡ = IU/L, § = Copy number/8.35µL as measured by qRT-PCR 
** = No raw or statistical analyses were performed with data from patient 6, draw 4 
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Table 4: Biomarker concordance with clinical assessments 
Patient  Draw # Clinical Assessment 
Concordance 
CTC PSA LDH miR-141 
1 
1 
Interval 1: Progressing rapidly (t = 2 months) 
Interval 2: Regressing slowly (t= 2 months) 
b b b b 
2 + + + + 
3 - + + - 
2 
1 
Interval 1: Progressing  slowly (t = 13 months) 
b b b b 
2 + + + + 
3 
1 Interval 1: Progressing rapidly during interval.  Patient died  4 
days after draw 2 with liver metastases (t = 3 months) 
b b b b 
2 + + + + 
4 
1 
Interval 1: Progressing  slowly (t = 11 months) 
b b b b 
2 + + - + 
5 
1 
Interval 1: Progressing slowly (t = 4 months) 
Interval 2: Stable on treatment (t = 21 days) 
b b b b 
2 + + + + 
3 - - - - 
6 
1 
Interval 1: Progressing rapidly (t = 2.5 months) 
Interval 2: Progressing slowly (t= 2.5 months) 
b b b b 
2 + + + + 
3 + + + + 
7 
1 
Interval 1: Regressing  slowly during interval (t = 4 months) 
b b b b 
2 - + + + 
8 
1 
Interval 1: Net slow regression (t = 3 months) 
Interval 2: Regressing rapidly (t= 20 days) 
b b b b 
2 + + + + 
3 + + - + 
9 
1 
Interval 1: Progressing slowly (t = 5 months) 
Interval 2: Regressing slowly (t= 7 months) 
b b b b 
2 - + + + 
3 + + N/A + 
10 
1 
Interval 1: Regressing  slowly during interval (t = 4 months) 
b b b b 
2 + + + + 
11 
1 
Interval 1: Regressing  slowly during interval (t = 2 months) 
b b b b 
2 + + + + 
12 
1 
Interval 1: Progressing slowly (t = 2 months) 
Interval 2: Regressing slowly (t= 4 months) 
b b b b 
2 + - - - 
3 + - + + 
13 
1 
Interval 1: Regressing rapidly during interval (t = 6 months) 
b b b b 
2 + + + + 
14 
1 
Interval 1: Progressing rapidly (t = 4.5 months)** 
b b b b 
2 - + + - 
15 
1 
Interval 1: Regressing slowly (t = 7 days) 
Interval 2: Net slow progression (t= 2.5 months) 
b b b b 
2 - + - - 
3 + + - + 
16 
1 
Interval 1: Progressing slowly (t = 5.5 months) 
Interval 2: Net slow progression (t= 2.5 months) 
b b b b 
2 + + - - 
3 + - N/A + 
17 
1 
Interval 1: Progressing slowly (t = 3.5 months) 
Interval 2: Rapid progression (t= 3 months) 
b  b b b 
2 + + + + 
3 + + + + 
18 
1 
Interval 1: Progressing slowly (t = 7 months) 
Interval 2: Slow progression (t= 1 month) 
b b b b 
2 + - + - 
3 + + - + 
19 
1 
Interval 1: Regressing slowly (t = 2 months) 
Interval 2: Slow regression (t= 2 months) 
b b b b 
2 + + + - 
3 + + + - 
20 
1 
Interval 1: Net slow progression (t = 4.5 months) 
Interval 2: Slow regression (t= 3 months) 
b b b b 
2 - + + + 
3 + + + + 
21 
1 
Interval 1: Slow regression (t = 2 months) 
Interval 2: Net Slow regression (t= 10.5 months) 
b b b b 
2 + + + + 
3 + + + + 
  # of intervals 34 34 34 34 
  number concordant 27 29 24 25 
  % Correct 79% 85% 71% 74% 
       
b = baseline, Interval 1 = time period between draw 1 and draw 2, Interval 2 = time period between draw 2 and draw 3 
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Figure 5: Fold changes in biomarker values for patients with 2 time points 
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Figure 6: Fold changes in biomarker values for patients with 3 time points 
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Table 5: Analysis of variance for cohort 1 (patients with 1 interval)  
 
 
 
Table 6: Analysis of variance analysis for cohort 2 (patients with 2 intervals) 
  
Marker 
PSA LDH CTC miR-141 
Group 1 
Mean 0.322 0.006 0.462 0.411 
           Std 0.262 0.042 0.702 0.493 
              N 8 8 8 8 
Group 2 
 Mean -0.436 -0.028 -0.853 -0.313 
Std 0.314 0.066 0.687 0.47 
N 8 8 8 8 
  
p-value <0.001 0.277 0.007 0.024 
 
Table 7: Correlation analysis for cohort 1 (patients with 1 interval)  
  
Marker 
vs. LDH vs. CTC vs. miR-141 
PSA 0.68 0.66 0.94 
  p=0.065 p=0.074 p<0.001 
LDH 
  
0.34 0.85 
  p=0.412 p=0.008 
CTC 
  
0.65 
  p=0.082 
 
 
  
Marker 
PSA LDH CTC miR-141 
Group 1 
Mean 0.189 0.308 0.13 0.394 
Std 0.178 0.531 0.479 0.59 
N 4 4 4 4 
Group 2 
 Mean -0.924 -0.105 -1.521 -0.869 
Std 0.135 0.04 1.967 0.194 
              N 4 4 4 4 
  
p-value <0.001 0.172 0.154 0.007 
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Table 8: Correlation analysis for cohort 2 (patients with 2 intervals) 
  
Marker 
vs. LDH vs. CTC vs. miR-141 
PSA 0.48 0.78 0.63 
  p=0.097 p=0.002 P=0.021 
LDH 
  
0.63 0.67 
  p=0.020 p=0.013 
CTC 
  
0.79 
  p=0.001 
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Table 9: Classification analysis for cohort 1 (patients with 1 interval) 
  Test Parameter 
  LDH CTC miR-141 
PSA (standard)  Decrease Increase Decrease Increase Decrease Increase 
Decrease 4 0 3 1 4 0 
Increase 1 3 1 3 1 3 
Sensitivity 75.00% 75.00% 75.00% 
Specificity 100.00% 75.00% 100.00% 
Correct 
classification 
87.50% 75.00% 87.50% 
LDH (standard)  
  
Decrease Increase Decrease Increase 
Decrease 3 2 4 1 
Increase 1 2 1 2 
Sensitivity 66.70% 66.70% 
Specificity 60.00% 80.00% 
Correct 
classification 
62.50% 75.00% 
CTC (standard)  
  
Decrease Increase 
Decrease 4 0 
Increase 1 3 
Sensitivity 75.00% 
Specificity 100.00% 
Correct 
classification 
87.50% 
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Table 10: Classification analysis for cohort 2 (patients with 2 intervals) 
  Test Parameter 
  LDH CTC miR-141 
PSA (standard)  Decrease Increase Decrease Increase Decrease Increase 
Decrease 4 1 5 0 4 1 
Increase 4 4 1 7 2 6 
Sensitivity 50.00% 87.50% 75.00% 
Specificity 80.00% 100.00% 80.00% 
Correct 
classification 
61.50% 92.30% 76.90% 
LDH (standard)  
  
Decrease Increase Decrease Increase 
Decrease 5 3 5 3 
Increase 1 4 1 4 
Sensitivity 80.00% 80.00% 
Specificity 62.50% 62.50% 
Correct 
classification 
69.20% 69.20% 
CTC (standard)  
  
Decrease Increase 
Decrease 5 1 
Increase 1 6 
Sensitivity 85.70% 
Specificity 83.30% 
Correct 
classification 
84.60% 
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CHAPTER 4 
DISCUSSION AND CONCLUSION 
There is great demand for more specific and sensitive biomarkers for 
prognosticating disease progression and determining treatment efficacy in CAP 
patients.  It is well known that PSA values can be affected by tumor 
differentiation state; where poorly differentiated tumors produce significantly less 
PSA compared to tumors with well differentiated cells.  Significant differences in 
PSA production can lead to false-negatives leading a patient to believe that he is 
cancer-free.  Despite its inherent shortfalls, the use of PSA levels as a diagnostic 
and prognostic marker has been the most commonly used test and seen as the 
gold standard in the detection and care of CAP.   
There has been major focus in discovering new biomarkers that will facilitate 
in the monitoring of disease progression.  Proper monitoring of disease 
progression throughout a treatment regimen is vital for increasing a patient’s 
chance of survival.  The monitoring of disease progression or treatment efficacy 
through the detection of biomarkers is ideal in that it requires a less invasive 
approach and limits potential harm and discomfort to the patient.  As mentioned, 
PSA is the gold standard in monitoring CAP; however new approaches such as 
detecting circulating tumor cells have been developed and is currently being 
used in conjunction with PSA tests. 
Discovering new biomarkers associated with disease states can be a 
daunting task.  Initial efforts in discovering new markers require “fishing” for any 
changes or expression levels compared to normal or non-disease cohorts.  
44 
Determining these changes requires numerous gene expression, microarray 
analyses or other experimental procedures that detect unique disease-
associated genetic signatures.  These experiments can even be complicated in 
the potential lack of samples or a model system.  Once a potential marker 
becomes identified, these candidate markers must prove to be sensitive and 
specific enough to be given approval for use in clinical testing. 
Markers currently approved for clinical use can help in validating a potential 
marker’s potential to indicate a possible disease state.  Candidate markers can 
use approved biomarkers as standards with which to compare its potential 
predictive characteristics.  More often, comparative studies would ideally be 
performed under a prospective study.  For this type of study, the expression of a 
putative marker should be determined or tested concomitantly with the standard 
marker.  Furthermore, marker values should be compared over time and 
determine if there is any correlation or concordance of changes comparable to 
the standard.  Prospective studies can prove to be difficult to establish due to 
potential lack in patients exhibiting the specific disease or the lack of tests being 
offered by certain facilities.  
In lieu of prospective studies, a retrospective study can be performed on 
samples collected and stored in biorepositories.  Many facilities proactively 
collect extra biological samples from patients in the anticipation of certain 
studies.  Unfortunately, retrospective studies can introduce bias in the sample 
selection or can risk the degradation of an analyte if the sample is not prepared 
or stored properly.  Nevertheless, a positive retrospective study can lead to a 
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prospective study if evidence suggests a strong correlation between the putative 
and standard marker.       
In this study, we took a retrospective approach to determine if detectable 
miRNA in CAP samples can accurately predict a patient’s prognosis.  An initial 
study (Mitchell et al., 2008) determined that miR-141 was stable and detectable 
in CAP in the plasma of patients.  We expanded on their study to compare miR-
141 with other conventional markers clinically approved for monitoring CAP 
prognosis.  Furthermore, these studies were performed temporally over either 
two or three draw points and determined if these changes over time correlated 
with the changes of the other conventional markers, and most importantly, if they 
there was concordance with the patient’s clinical outcome. 
Although we detected miR-141 in our control population, the control data 
proved to be inconclusive.  Since control samples are healthy individuals, no 
follow-up samples were collected leaving us with only one data point per control; 
therefore we cannot determine any temporal changes.  Furthermore, no other 
clinical values were ascertained limiting our ability to compare the miR-141 
values against other markers.  The individual data points also demonstrate an 
inability to establish any baseline values that can distinguish a healthy individual 
from a diseased individual. 
We observed a range of miR-141 values from our control samples of1.6 
(control sample 10) to 1997 (control sample 1) copy numbers – a difference of 
over 1000 fold.  However, analyzing the control miR-141 values broken down into 
ranges illustrate that 80% of the samples fell between ranges of 1- 300 copy 
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numbers, whereas the remaining fell in the range of 1000 or more.   It would be 
easy for us to classify the spike in these two samples as outliers from the 
remainder of the group, but unfortunately, the control patients were kept 
anonymous and their health status was not clinically validated.  Perhaps this 
illustrates miR-141’s involvement in processes we are not quite aware of at the 
moment.   An improvement for a study like this would be the ability to include 
validated health statues on control samples.  Nonetheless, we found significant 
findings in the changes of miR-141 for patients who have progressing or 
regressing CAP. 
We first sought to determine if raw values of miR-141 could accurately predict 
a clinical response by determining any degree of concordance that miR-141 
values had with the true clinical assessments.  For all of our comparison studies, 
PSA was used as the standard. PSA had an 85% concordance with the clinical 
assessments whereas CTC and miR-141 had a 79% and 74% concordance, 
respectively.  This analysis clearly illustrates that, although PSA is considered 
the benchmark marker, there is no test that can predict a clinical response with 
100% accuracy for CAP.  Furthermore, it illustrates that miR-141 has predictive 
qualities that can potentially discern a clinical assessment. 
Our initial ANOVA study clearly indicates (as expected) that PSA is capable 
of differentiating the difference of a progressing or regressing CAP patient.  For 
both cohorts, p-value for PSA of p<0.001 is a strong indicator that the differences 
between the two groups were not by random chance alone.  As we compared the 
miR-141 p-values, we observed fairly significant values (p=0.007 and p=0.024 for 
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cohort 1 and 2, respectively).  Meaning, to some degree of confidence, we can 
differentiate groups of patients based on miR-141 values.  Comparing these p-
values to LDH and CTC for those in cohort 1, we confidently say that miR-141 
outperforms LDH and CTC in its ability to properly classify CAP prognosis in 
patients with one interval.  However, in patients with two interval (cohort 2), the 
performance of miR-141 was not as impressive and was outperformed by CTC 
(p=0.007CTC vs. p=0.024miR-141).  An important observation was made in that LDH 
did not outperform any markers in any of the two cohorts for this particular study 
Our study of variance also illustrated a high coefficient of variation (CV) 
observed for each group and in each cohort with CVs ranging from 30% or 
greater.  For a translational study such as this, it would be important to limit this 
CV to 10% or less.  To achieve this, we would need to determine what would be 
the sufficient sample size for ensuring a CV of our ideal percentage.  Using our 
observed means for each marker studied, a confidence interval of 99%  and 
limiting the margin of error to 1%, it is estimated that we would have needed to 
study 663 patients achieve a CV of 10% or less.   
We conducted a correlation study to compare the predictive relationship of 
each marker versus the standard (PSA).  We observed a high correlation 
(R=0.94, p<0.001) of miR-141 for cohort 1; however, these values decreased in 
cohort 2 (R=0.63, p=0.021).  Again, the performance of miR-141 in the 
correlation study for cohort 1 was significantly better than both CTC and LDH, but 
this cannot be said in cohort 2.  In cohort 2, CTC (R=0.78, p=0.002) clearly 
outperformed the other two analytes.  Also for cohort 2, we observed a 
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signification correlation between CTC and miR-141 values (R=0.79, p=0.001), 
thus allowing us to conclude that there could potentially be a synergistic quality 
between these two analytes in prognosticating CAP.   
As for any medical test, it is necessary to determine the predictive value and 
accuracy of test in order to be used for clinical settings. To conclude our 
statistical analysis of biomarker comparisons, we performed a binary 
classification analysis to determine the sensitivity (true positives) and specificity 
(true negatives) of a marker in relation to a gold standard.  Performing this type 
of comparison would allow us to further conclude the capability that miR-141 can 
screen and confirm a CAP prognosis.  This test indicated that miR-141 had 
strong classification characteristics compared to CTC and LDH.  Although we 
only observed an 80% specificity (compared to PSA as gold standard) for cohort 
2, we were able to observe 100% specificity for cohort 1.  Furthermore, 
comparing the sensitivity and specificity of LDH and CTC against PSA, miR-141 
performed better than LDH and comparable to CTC in this classification analysis.  
Ideally, any test should have sensitivity and specificity close to 100%, but no 
such perfect test exists for CAP.   
Our study was designed to evaluate the performance of miR-141 in predicting 
clinical outcomes in CAP patients.  Our goal was to determine if temporal 
changes of miR-141 correlated with the clinical outcomes of patients and if these 
changes concomitantly changed with other conventional biomarkers used in 
monitoring and prognosticating CAP.  The study of raw temporal changes, 
however, did not allow us to determine a baseline miR-141 copy number value 
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that can accurately predict a clinical outcome (meaning we cannot determine an 
upper limit of normal).  Determining a threshold or baseline miR-141 value would 
require a more extensive study involving more patients. 
Our statistical analyses were performed on the slopes determined from 
plotting two interval points; these slopes are interpreted as the rate of biomarker 
change over time.  The analysis compared miR-141 changes to the rates of 
change observed in the other clinical markers.   The correlation and classification 
analyses indicate that miR-141 has the potential to be a new biomarker for the 
progression of CAP.  In some instances, miR-141 outperformed CTCs but in all 
cases it performed better than LDH. 
For this study, no inference can be made on the mechanisms for miR-141 
detection in the bloodstream.  However, our ANOVA analysis may point to a link 
with PSA and miR-141 secretion into the bloodstream.  Perhaps there can also 
be a link with miR-141 values and CTCs detected wherein a CTC could possibly 
undergo apoptosis or lyse releasing miR-141; however, further characterization 
and mechanism of CTC release is needed to characterize any potential links.  
Nonetheless, this retrospective study provides evidence that miR-141 has 
potential to aid in prognosticating CAP progression or predict response to 
treatment; however additional studies need to be performed prospectively with a 
much larger sample population to confirm the utility of miR-141.          
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APPENDIX 
SUPPLEMENTAL DATA 
Table A1: Summary of preliminary data obtained our study 
 
Disease  Platform 
Analyte 
Type 
Analyte Status 
Breast 
cancer 
Luminex® Protein 
CA-125, IGF-II, Leptin, 
MIF, Osteopontin, 
Prolactin 
Sample procurement 
issues hindered further 
results 
qRT-PCR 
Gene 
Expression 
BMI1 and SALL4 
Preliminary results 
obtained 
Prostate 
Cancer 
Luminex® Protein BMI1 and SALL4 
Sample procurement 
issue hindered 
preliminary results 
qRT-PCR 
Gene 
Expression 
BMI1 and SALL4 
Degradation of analyte 
yielded no results 
qRT-PCR microRNA miR-141 Pilot study completed 
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Figure A1: 6-analyte assay of breast cancer patients.  Samples of serum normal 
women and breast cancer patients were subjected to a 6-analyte, Luminex®-
based biomarker panel obtained from Millipore.    Our objective was to determine 
the utility of this marketed biomarker panel in detecting and differentiating breast 
cancer patients from normal samples.  Policies in samples procurement hindered 
attempts to follow-up with results and perform more studies. 
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Figure A2: SALL4 and BMI1 gene expression assay on breast cancer patient 
serum.  In-house developed multiplex TaqMan gene expression assay was 
performed to determine relative quantification of SALL4 and BMI1 in breast 
cancer patients with varying stages of disease progression.  Policies in samples 
procurement hindered attempts to follow-up with results and perform more 
studies.  
Gene Expression of Bmi1
0.01
0.1
1
10
100
1000
10000
R
e
la
ti
v
e
 Q
u
a
n
ti
fi
c
a
ti
o
n
 (
L
o
g
)
Controls Stage I/II Stage III/IV
Gene Expression of SALL4
0.1
1
10
100
1000
10000
100000
R
e
la
ti
v
e
 Q
u
a
ti
fi
c
a
ti
o
n
 (
L
o
g
)
Controls Stage I/II Stage III/IV
53 
REFERENCES 
1. Heron, M. P., Hoyert, D. L., Murphy, S. L., Xu, J. Q., Kochanek, K. D., and 
Tejada-Vera, B. (2009) Deaths: Final data for 2006, in National vital 
statistics reports, National Center for Health Statistics, Hyattsville, MD. 
2. Boyle, P., and Levin, B. (2008) World Cancer Report 2008. 
3. Society, A. C. (2009) Cancer Facts & Figures, American Cancer Society, 
Atlanta. 
4. Bostwick, D. G. High-grade prostatic intraepithelial neoplasia: The most likely 
precursor of prostate cancer, Cancer 75, 1823-1836. 
5. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T. 
C., Willi, N., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. (1999) 
Survey of gene amplifications during prostate cancer progression by high-
throughout fluorescence in situ hybridization on tissue microarrays, 
Cancer Res 59, 803-806. 
6. Buttyan, R., Sawczu, I. S., Benson, M. C., Siegal, J. D., and Olsson, C. A. 
(1977) Enhanced expression of the c-myc protooncogene in high-grade 
human prostate cancers, Prostate 11, 327-337. 
7. Jenkins, R. B., Qian, J., Lieber, M. M., and Bostwick, D. G. (1997) Detection 
of c-myc oncogene amplification and chromosomal anomalies in 
metastatic prostatic carcinoma by fluorescence in situ hybridization, 
Cancer Res 57, 524-531. 
8. Nupponen, N. N., Kakkola, L., Koivisto, P., and Visakorpi, T. (1998) Genetic 
alterations in hormone-refractory recurrent prostate carcinomas, Am J 
Pathol 153, 141-148. 
9. Sato, K., Qian, J., Slezak, J. M., Lieber, M. M., Bostwick, D. G., Bergstralh, E. 
J., and Jenkins, R. B. (1999) Clinical significance of alterations of 
chromosome 8 in high-grade, advanced, nonmetastatic prostate 
carcinoma, J Natl Cancer Inst 91, 1574-1580. 
10. Carter, B. S., Epstein, J. I., and Isaacs, W. B. (1990) ras gene mutations in 
human prostate cancer, Cancer Res 50, 6830-6832. 
11. Gumerlock, P. H., Poonamallee, U. R., Meyers, F. J., and White, R. W. d. 
(1991) Activated ras alleles in human carcinoma of the prostate are rare, 
Cancer Res 51, 1632-1637. 
12. Shiraishi, T., Muneyuki, T., Fukutome, K., Ito, H., Kotake, T., Watanabe, M., 
and Yatani, R. (1998) Mutations of ras genes are relatively frequent in 
Japanese prostate cancers: pointing to genetic differences between 
populations, Anticancer Res 18, 2789-2792. 
13. Konishi, N., Hiasa, Y., Tsuzuki, T., M, M. T., Enomoto, T., and Miller, G. J. 
(1997) Comparison of ras activation in prostate carcinoma in Japanese 
and American men, Prostate 30, 53-57. 
14. Liu, L., Yoon, J. H., Dammann, R., and Pfeifer, G. P. (2002) Frequent 
hypermethylation of the RASSF1A gene in prostate cancer, Oncogene 21, 
6835-6840. 
15. DiCristofano, A., and Pandolfi, P. P. (2000) The multiple roles of PTEN in 
tumor suppression, Cell 100, 387. 
54 
16. Mirchandan, D., Zheng, J., Miller, G. J., Ghosh, A. K., Shibata, D. K., Cote, R. 
J., and Roy-Burman, P. (1995) Heterogeneity in intratumor distribution of 
p53 mutations in human prostate cancer, Am J Pathol 147, 92-101. 
17. Meyers, F. J., Gumerlock, P. H., Chi, S. G., Borchers, H., Deitch, A. D., and 
White, R. W. d. (1998) Very frequent p53 mutations in metastatic prostate 
carcinoma and in matched primary tumors, Cancer 83, 2534-2539. 
18. Noordzij, M. A., Steenbrugge, G. J. v., Schroder, F. H., and Kwast, T. H. V. d. 
(1999) Decreased expression of CD44 in metastatic prostate cancer, Int J 
Cancer 84, 478-483. 
19. Noordzij, M. A., Steenbrugge, G. J. v., Verkaik, N. S., Schroder, F. H., and 
Kwast, T. H. v. d. (1997) The prognostic value of CD44 isoforms in 
prostate cancer patients treated by radical prostatectomy, Clin Cancer 
Res 3, 805-815. 
20. Nagabhushan, M., Pretlow, T. G., Guo, Y. J., Amini, S. B., Pretlow, T. P., and 
Sy, M. S. (1996) Altered expression of CD44 in human prostate cancer 
during progression, Am J Clin Pathol 106, 647-651. 
21. Gunthert, U., Stauder, R., Mayer, B., Terpe, H. J., Finke, L., and Friedrichs, K. 
(1995) Are CD44 variant isoforms involved in human tumour progression?, 
Cancer Surv 24, 19-42. 
22. Cude, K. J., Dixon, S. C., Guo, Y., Lisella, J., and Figg, W. D. (1999) The 
androgen receptor: genetic considerations in the development and 
treatment of prostate cancer, J Mol Med 77, 419-426. 
23. Gonzalgo, M. L., and Isaacs, W. B. (2003) Molecular pathways to prostate 
cancer, J Urol 170, 2444-2452. 
24. Nelson, W. G., Marzo, A. M. D., and Isaacs, W. B. (2003) Prostate cancer, N 
Engl J Med 349, 366. 
25. Berg, J. M., Tymoczko, J. L., and Stryer, L. (2002) Biochemistry, 5 ed., New 
York. 
26. Denmeade, S. R., Lin, X. S., and Isaacs, J. T. (1996) Role of programmed 
(apoptotic) cell death during the progression and therapy for prostate 
cancer, Prostate 28, 251-265. 
27. Lu, S., Tsai, S. Y., and Tsai, M. J. (1997) Regulation of androgen-dependent 
prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and 
CKI p16 genes, Cancer Res 57, 4511-4516. 
28. Kyprianou, N., English, H. F., and Isaacs, J. T. (1990) Programmed cell death 
during regression of PC-82 human prostate cancer following androgen 
ablation, Cancer Res 50, 3748-3753. 
29. Gao, J., and Isaacs, J. T. (1998) Development of an androgen receptor-null 
model for identifying the initiation site for androgen stimulation of 
proliferation and suppression of programmed (apoptotic) death of PC-82 
human prostate cancer cells, Cancer Res 58, 3299-3306. 
30. Feldman, B. J., and Feldman, D. (2001) The development of androgen-
independent prostate cancer, Nat Rev Cancer 1, 34-45. 
31. Catz, S. D., and Johnson, J. L. (2003) BCL-2 in prostate cancer: a minireview, 
Apoptosis 8, 29-37. 
55 
32. Isaacs, J. T. (1999) The biology of hormone refractory prostate cancer. Why 
does it develop?, Urol Clin North Am 26, 263-273. 
33. Altekruse, S. F., Kosary, C. L., Krapcho, M., Neyman, N., Aminou, R., 
Waldron, W., Ruhl, J., Howlader, N., Tatalovich, Z., Cho, H., Mariotto, A., 
Eisner, M. P., Lewis, D. R., Cronin, K., Chen, H. S., Feuer, E. J., 
Stinchcomb, D. G., and Edwards, B. K. (2010) SEER Cancer Statistics 
Review, 1975-2007, National Cancer Institute, Bethesda, MD. 
34. Hankey, B. F., Feuer, E. J., Clegg, L. X., Hayes, R. B., Legler, J. M., Prorok, 
P. C., Ries, L. A., Merrill, R. M., and Kaplan, R. S. (1999) Cancer 
surveillance series: interpreting trends in prostate cancer--part I: Evidence 
of the effects of screening in recent prostate cancer incidence, mortality, 
and survival rates, J Natl Cancer Inst 91, 1017-1024. 
35. Delongchamps, N. B., Singh, A., and Haas, G. P. (2006) The role of 
prevalence in the diagnosis of prostate cancer, Cancer Control 13, 158-
168. 
36. Baquet, C. R., Horm, J. W., Gibbs, T., and Greenwald, P. (1991) 
Socioeconomic factors and cancer incidence among blacks and whites, J 
Natl Cancer Inst 83, 551-557. 
37. Ingle, S. A., Coetzee, G. A., Ross, R. K., Henderson, B. E., Kolonel, L. N., 
Crocitto, L., Wang, W., and Haile, R. W. (1998) Association of prostate 
cancer with vitamin D receptor haplotypes in African-Americans, Cancer 
Res 58, 1620-1623. 
38. Platz, E. A., Rimm, E. B., Willett, W. C., Kantoff, P. W., and Giovannucci, E. 
(2000) Racial variation in prostate cancer incidence and in hormonal 
system markers among male health professional, J Natl Cancer Inst 92, 
2009-2017. 
39. Hoffman, R. M., Gilliland, F. D., Eley, J. W., Harlan, L. C., Stephenson, R. A., 
Stanford, J. L., Albertson, P. C., Hamilton, A. S., Hunt, W. C., and 
Potosky, A. L. (2001) Racial and ethnic differences in advanced-stage 
prostate cancer: the Prostate Cancer Outcomes Study, J Natl Cancer Inst 
93, 388-395. 
40. Cross, C. K., Shultz, D., Malkowicz, S. B., Huang, W. C., Whittington, R., 
Tomaszewski, J. E., Renshaw, A. A., Richie, J. P., and D'Amico, A. V. 
(2002) Impact of race on prostate-specific antigen outcome after radical 
prostatectomy for clinically localized adenocarcinoma of the prostate, J 
Clin Oncol 20, 2863-2868. 
41. Bennett, C. L., Ferreira, M. R., Davis, T. C., Kaplan, J., Weinberger, M., 
Kuzel, T., Seday, M. A., and Sartor, O. (1998) Relation between literacy, 
race, and stage of presentation among low-income patients with prostate 
cancer, J Clin Oncol 16, 3101-3104. 
42. Whittemore, A. S., Wu, A. H., Kolonel, L. N., EM, E. M. J., Gallagher, R. P., 
Howe, G. R., West, D. W., CZ, C. Z. T., and Stamey, T. (1995) Family 
history and prostate cancer risk in black, white, and Asian men in the 
United States and Canada, Am J Epidemiol 141, 732-740. 
56 
43. Steinberg, G. D., Carter, B. S., Beaty, T. H., Childs, B., and Walsh, P. C. 
(1990) Family history and the risk of prostate cancer, Prostate 17, 334-
347. 
44. Zeegerse, M. P., Jellema, A., and Ostrer, H. (2003) Empiric risk of prostate 
carcinoma for relatives of patients with prostate carcinoma: a meta-
analysis, Cancer 97, 1894-1903. 
45. Bruner, D. W., Moore, D., Parlanti, A., Dorgan, J., and Engstrom, P. (2003) 
Relative risk of prostate cancer for men with affected relatives: systematic 
review and meta-analysis, Int J Cancer 107, 797-803. 
46. Hemminki, K., and Czene, K. (2002) Age specific and attributable risks of 
familial prostate carcinoma from the family-cancer database, Cancer 95, 
1346-1353. 
47. Valeri, A., Cormier, L., Moineau, M. P., Cancel-Tassin, G., Azzouzi, R., 
Doucet, L., Baschet, F., Cussenot, I., L'Her, J., Berthon, P., Mangin, P., 
Cussenot, O., Morin, J. F., and Fournier, G. (2002) Targeted screening for 
prostate cancer in high risk families: early onset is a significant risk factor 
for disease in first degree relatives, J Urol 168, 483-487. 
48. Hemminki, K., Ji, J., Forsti, A., Sundquist, J., and Lenner, P. (2008) 
Concordance of survival in family members with prostate cancer, J Clin 
Oncol 26, 1705-1709. 
49. Dorr, V. J., Williamson, S. K., and Stephens, R. L. (1993) An evaluation of 
prostate-specific antigen as a screening test for prostate cancer, Arch 
Intern Med 153, 2529. 
50. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., and 
Redwine, E. (1987) Prostate-specific antigen as a serum marker for 
adenocarcinoma of the prostate, N Engl J Med 317, 909-916. 
51. Tchetgen, M. B., and Oesterling, J. E. (1997) The effect of prostatitis, urinary 
retention, ejaculation, and ambulation on the serum prostate-specific 
antigen concentration, Urol Clin North Am 24, 283-291. 
52. Chybowski, F. M., Bergstralh, E. J., and Oesterling, J. E. (1992) The effect of 
digital rectal examination on the serum prostate specific antigen 
concentration: results of a randomized study, J Urol 148, 83-86. 
53. (1995) Effect of digital rectal examination on serum prostate-specific antigen 
in a primary care setting, Arch Intern Med 155, 389. 
54. Herschman, J. D., Smith, D. S., and Catalona, W. J. (1997) Effect of 
ejaculation on serum total and free prostate-specific antigen 
concentrations, Urology 50, 239-243. 
55. Tchetgen, M. B., Song, J. T., Strawderman, M., Jacobsen, S. J., and 
Oesterling, J. E. (1996) Ejaculation increases the serum prostate-specific 
antigen concentration, Urology 47, 511-516. 
56. Kawakami, J., Siemens, D. R., and Nickel, J. C. (2004) Prostatitis and 
prostate cancer: implications for prostate cancer screening, Urology 64, 
1075-1080. 
57. Brawer, M. K. (1999) Prostate-specific antigen: current status, CA Cancer J 
Clin 49, 264-281. 
57 
58. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L., and 
Lange, P. H. (1992) Screening for prostatic carcinoma with prostate 
specific antigen, J Urol 147, 841-845. 
59. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., 
Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. 
L., and et al. (1994) Comparison of digital rectal examination and serum 
prostate specific antigen in the early detection of prostate cancer: results 
of a multicenter clinical trial of 6,630 men, J Urol 151, 1283-1290. 
60. Schroder, F. H., van der Cruijsen-Koeter, I., de Koning, H. J., Vis, A. N., 
Hoedemaeker, R. F., and Kranse, R. (2000) Prostate cancer detection at 
low prostate specific antigen, J Urol 163, 806-812. 
61. Coley, C. M., Barry, M. J., Fleming, C., and Mulley, A. G. (1997) Early 
detection of prostate cancer. Part I: Prior probability and effectiveness of 
tests. The American College of Physicians, Ann Intern Med 126, 394-406. 
62. Polascik, T. J., Oesterling, J. E., and Partin, A. W. (1999) Prostate specific 
antigen: a decade of discovery--what we have learned and where we are 
going, J Urol 162, 293-306. 
63. Catalona, W. J., Smith, D. S., and Ornstein, D. K. (1997) Prostate cancer 
detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and 
benign prostate examination. Enhancement of specificity with free PSA 
measurements, JAMA 277, 1452-1455. 
64. Babaian, R. J., Johnston, D. A., Naccarato, W., Ayala, A., Bhadkamkar, V. A., 
and Fritsche, H. H., Jr. (2001) The incidence of prostate cancer in a 
screening population with a serum prostate specific antigen between 2.5 
and 4.0 ng/ml: relation to biopsy strategy, J Urol 165, 757-760. 
65. Gilbert, S. M., Cavallo, C. B., Kahane, H., and Lowe, F. C. (2005) Evidence 
suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: 
review of 36,316 biopsies, Urology 65, 549-553. 
66. Porter, M. P., Stanford, J. L., and Lange, P. H. (2006) The distribution of 
serum prostate-specific antigen levels among American men: implications 
for prostate cancer prevalence and screening, Prostate 66, 1044-1051. 
67. Epstein, J. I. (2002) Pathology of prostatic neoplasia, in Campbell's Urology 
(Walsh, P. C., Ed.) 8 ed., Saunders, Philadelphia. 
68. Chodak, G. W., Keller, P., and Schoenberg, H. W. (1989) Assessment of 
screening for prostate cancer using the digital rectal examination, J Urol 
141, 1136-1138. 
69. Hoogendam, A., Buntinx, F., and de Vet, H. C. (1999) The diagnostic value of 
digital rectal examination in primary care screening for prostate cancer: a 
meta-analysis, Fam Pract 16, 621-626. 
70. Richie, J. P., Catalona, W. J., Ahmann, F. R., Hudson, M. A., Scardino, P. T., 
Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. 
L., and et al. (1993) Effect of patient age on early detection of prostate 
cancer with serum prostate-specific antigen and digital rectal examination, 
Urology 42, 365-374. 
58 
71. Rifkin, M. D., Alexander, A. A., Pisarchick, J., and Matteucci, T. (1991) 
Palpable masses in the prostate: superior accuracy of US-guided biopsy 
compared with accuracy of digitally guided biopsy, Radiology 179, 41-42. 
72. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., 
Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. 
D., Crowley, J. J., and Coltman, C. A., Jr. (2004) Prevalence of prostate 
cancer among men with a prostate-specific antigen level < or =4.0 ng per 
milliliter, N Engl J Med 350, 2239-2246. 
73. Carter, H. B. (2004) Prostate cancers in men with low PSA levels--must we 
find them?, N Engl J Med 350, 2292-2294. 
74. Smith, D. S., Catalona, W. J., and Herschman, J. D. (1996) Longitudinal 
screening for prostate cancer with prostate-specific antigen, JAMA 276, 
1309-1315. 
75. Hoedemaeker, R. F., van der Kwast, T. H., Boer, R., de Koning, H. J., 
Roobol, M., Vis, A. N., and Schroder, F. H. (2001) Pathologic features of 
prostate cancer found at population-based screening with a four-year 
interval, J Natl Cancer Inst 93, 1153-1158. 
76. Gleason, D. F., and Mellinger, G. T. (1974) Prediction of prognosis for 
prostatic adenocarcinoma by combined histological grading and clinical 
staging, J Urol 111, 58-64. 
77. Bostwick, D. G. (1994) Gleason grading of prostatic needle biopsies. 
Correlation with grade in 316 matched prostatectomies, Am J Surg Pathol 
18, 796-803. 
78. Epstein, J. I. An update of the Gleason grading system, J Urol 183, 433-440. 
79. Egevad, L., Norberg, M., Mattson, S., Norlen, B. J., and Busch, C. (1998) 
Estimation of prostate cancer volume by multiple core biopsies before 
radical prostatectomy, Urology 52, 653-658. 
80. Sebo, T. J., Cheville, J. C., Riehle, D. L., Lohse, C. M., Pankratz, V. S., 
Myers, R. P., Blute, M. L., and Zincke, H. (2001) Predicting prostate 
carcinoma volume and stage at radical prostatectomy by assessing 
needle biopsy specimens for percent surface area and cores positive for 
carcinoma, perineural invasion, Gleason score, DNA ploidy and 
proliferation, and preoperative serum prostate specific antigen: a report of 
454 cases, Cancer 91, 2196-2204. 
81. Andriole, G. L., Crawford, E. D., Grubb, R. L., 3rd, Buys, S. S., Chia, D., 
Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., 
Weissfeld, J. L., Yokochi, L. A., O'Brien, B., Clapp, J. D., Rathmell, J. M., 
Riley, T. L., Hayes, R. B., Kramer, B. S., Izmirlian, G., Miller, A. B., Pinsky, 
P. F., Prorok, P. C., Gohagan, J. K., and Berg, C. D. (2009) Mortality 
results from a randomized prostate-cancer screening trial, N Engl J Med 
360, 1310-1319. 
82. Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Ciatto, S., 
Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., 
Recker, F., Berenguer, A., Maattanen, L., Bangma, C. H., Aus, G., Villers, 
A., Rebillard, X., van der Kwast, T., Blijenberg, B. G., Moss, S. M., de 
59 
Koning, H. J., and Auvinen, A. (2009) Screening and prostate-cancer 
mortality in a randomized European study, N Engl J Med 360, 1320-1328. 
83. Essink-Bot, M. L., de Koning, H. J., Nijs, H. G., Kirkels, W. J., van der Maas, 
P. J., and Schroder, F. H. (1998) Short-term effects of population-based 
screening for prostate cancer on health-related quality of life, J Natl 
Cancer Inst 90, 925-931. 
84. Rietbergen, J. B., Kruger, A. E., Kranse, R., and Schroder, F. H. (1997) 
Complications of transrectal ultrasound-guided systematic sextant 
biopsies of the prostate: evaluation of complication rates and risk factors 
within a population-based screening program, Urology 49, 875-880. 
85. Klotz, L. H. (1997) PSAdynia and other PSA-related syndromes: a new 
epidemic--a case history and taxonomy, Urology 50, 831-832. 
86. Bracarda, S., de Cobelli, O., Greco, C., Prayer-Galetti, T., Valdagni, R., Gatta, 
G., de Braud, F., and Bartsch, G. (2005) Cancer of the prostate, Crit Rev 
Oncol Hematol 56, 379-396. 
87. Klotz, L. (2007) Active surveillance for favorable-risk prostate cancer: who, 
how and why?, Nat Clin Pract Oncol 4, 692-698. 
88. Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., 
Cookson, M. S., D'Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, 
J. D., Goldenberg, S. L., Hernandez, J., Higano, C. S., Kraus, S. R., Moul, 
J. W., and Tangen, C. M. (2007) Guideline for the management of 
clinically localized prostate cancer: 2007 update, J Urol 177, 2106-2131. 
89. Roodman, G. D. (2001) Biology of osteoclast activation in cancer, J Clin 
Oncol 19, 3562-3571. 
90. Yagoda, A., and Petrylak, D. (1993) Cytotoxic chemotherapy for advanced 
hormone-resistant prostate cancer, Cancer 71, 1098-1109. 
91. Bot, A. The landmark approval of Provenge, what it means to immunology 
and "in this issue": the complex relation between vaccines and 
autoimmunity, Int Rev Immunol 29, 235-238. 
92. Vishnu, P., and Tan, W. W. Update on options for treatment of metastatic 
castration-resistant prostate cancer, Onco Targets Ther 3, 39-51. 
93. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., 
Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., Xu, 
Y., Frohlich, M. W., and Schellhammer, P. F. Sipuleucel-T immunotherapy 
for castration-resistant prostate cancer, N Engl J Med 363, 411-422. 
94. (2001) Biomarkers and surrogate endpoints: preferred definitions and 
conceptual framework, Clin Pharmacol Ther 69, 89-95. 
95. Lovgren, J., Valtonen-Andre, C., Marsal, K., Lilja, H., and Lundwall, A. (1999) 
Measurement of prostate-specific antigen and human glandular kallikrein 
2 in different body fluids, J Androl 20, 348-355. 
96. Sensabaugh, G. F. (1978) Isolation and characterization of a semen-specific 
protein from human seminal plasma: a potential new marker for semen 
identification, J Forensic Sci 23, 106-115. 
97. Cohn, J. N. (2004) Introduction to surrogate markers, Circulation 109, IV20-
21. 
60 
98. Gallagher, D. J., Milowsky, M. I., Ishill, N., Trout, A., Boyle, M. G., Riches, J., 
Fleisher, M., and Bajorin, D. F. (2009) Detection of circulating tumor cells 
in patients with urothelial cancer, Ann Oncol 20, 305-308. 
99. Massard, C., Chauchereau, A., and Fizazi, K. (2009) The quest for the 'bony 
Grail' of detecting circulating tumour cells in patients with prostate cancer, 
Ann Oncol 20, 197-199. 
100. Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., 
Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., Doyle, G. V., 
Tissing, H., Terstappen, L. W., and Meropol, N. J. (2008) Relationship of 
circulating tumor cells to tumor response, progression-free survival, and 
overall survival in patients with metastatic colorectal cancer, J Clin Oncol 
26, 3213-3221. 
101. Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. 
C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W., and 
Hayes, D. F. (2004) Circulating tumor cells, disease progression, and 
survival in metastatic breast cancer, N Engl J Med 351, 781-791. 
102. Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, 
A., Tanaka, E., Lilja, H., Schwartz, L., Larson, S., Fleisher, M., and Scher, 
H. I. (2007) Circulating Tumor Cell Number and Prognosis in Progressive 
Castration-Resistant Prostate Cancer, Clin Cancer Res 13, 7053-7058. 
103. de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., 
Tissing, H., Doyle, G. V., Terstappen, L. W., Pienta, K. J., and Raghavan, 
D. (2008) Circulating tumor cells predict survival benefit from treatment in 
metastatic castration-resistant prostate cancer, Clin Cancer Res 14, 6302-
6309. 
104. Olmos, D., Arkenau, H. T., Ang, J. E., Ledaki, I., Attard, G., Carden, C. P., 
Reid, A. H., A'Hern, R., Fong, P. C., Oomen, N. B., Molife, R., Dearnaley, 
D., Parker, C., Terstappen, L. W., and de Bono, J. S. (2009) Circulating 
tumour cell (CTC) counts as intermediate end points in castration-resistant 
prostate cancer (CRPC): a single-centre experience, Ann Oncol 20, 27-33. 
105. Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and 
function, Cell 116, 281-297. 
106. Lund, E., Guttinger, S., Calado, A., Dahlberg, J. E., and Kutay, U. (2004) 
Nuclear export of microRNA precursors, Science 303, 95-98. 
107. Ambion. (2010) microRNAs: Processing Austin. 
108. Griffiths-Jones, S., Grocock, R. J., van Dongen, S., Bateman, A., and 
Enright, A. J. (2006) miRBase: microRNA sequences, targets and gene 
nomenclature, Nucleic Acids Res 34, D140-144. 
109. Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993) The C. elegans 
heterochronic gene lin-4 encodes small RNAs with antisense 
complementarity to lin-14, Cell 75, 843-854. 
110. Ambros, V. (2004) The functions of animal microRNAs, Nature 431, 350-
355. 
111. Singh, S. K., Pal Bhadra, M., Girschick, H. J., and Bhadra, U. (2008) 
MicroRNAs - micro in size but macro in function, FEBS J. 
61 
112. Fulci, V., Chiaretti, S., Goldoni, M., Azzalin, G., Carucci, N., Tavolaro, S., 
Castellano, L., Magrelli, A., Citarella, F., Messina, M., Maggio, R., 
Peragine, N., Santangelo, S., Mauro, F. R., Landgraf, P., Tuschl, T., Weir, 
D. B., Chien, M., Russo, J. J., Ju, J., Sheridan, R., Sander, C., Zavolan, 
M., Guarini, A., Foa, R., and Macino, G. (2007) Quantitative technologies 
establish a novel microRNA profile of chronic lymphocytic leukemia, Blood 
109, 4944-4951. 
113. Jazdzewski, K., Liyanarachchi, S., Swierniak, M., Pachucki, J., Ringel, M. 
D., Jarzab, B., and Chapelle, A. d. l. (2009) Polymorphic mature 
microRNAs from passenger strand of pre-miR-146a contribute to thyroid 
cancer., Proc Natl Acad Sci 106, 1502-1505. 
114. Roa, W., Brunet, B., Guo, L., Amanie, J., Fairchild, A., Gabos, Z., Nijjar, 
T., Scrimger, R., Yee, D., and Xing, J. Identification of a new microRNA 
expression profile as a potential cancer screening tool, Clin Invest Med 33, 
E124. 
115. Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., 
Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., 
Allen, A., Lin, D. W., Urban, N., Drescher, C. W., Knudsen, B. S., 
Stirewalt, D. L., Gentleman, R., Vessella, R. L., Nelson, P. S., Martin, D. 
B., and Tewari, M. (2008) Circulating microRNAs as stable blood-based 
markers for cancer detection, Proc Natl Acad Sci U S A 105, 10513-
10518. 
116. Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., 
Farshid, G., Vadas, M. A., Khew-Goodall, Y., and Goodall, G. J. (2008) 
The miR-200 family and miR-205 regulate epithelial to mesenchymal 
transition by targeting ZEB1 and SIP1, Nat Cell Biol 10, 593-601. 
117. Miska, E. A. (2008) MicroRNAs--keeping cells in formation, Nat Cell Biol 
10, 501-502. 
118. Park, S. M., Gaur, A. B., Lengyel, E., and Peter, M. E. (2008) The miR-
200 family determines the epithelial phenotype of cancer cells by targeting 
the E-cadherin repressors ZEB1 and ZEB2, Genes Dev 22, 894-907. 
 
 
62 
VITA 
Graduate College 
University of Nevada, Las Vegas 
 
Jason Cadaoas Gonzales 
Degrees: 
 Bachelor of Science, Biology, 2004 
 University of Nevada, Las Vegas 
 
Publications: 
Kim, H. E., Symanowski, J. T., Samlowski, E. E., Gonzales, J., and Ryu, B. 
(2010) Quantitative measurement of circulating lymphoid-specific helicase 
(HELLS) gene transcript: a potential serum biomarker for melanoma 
metastasis, Pigment Cell Melanoma Res 23, 845. 
 
Thesis Title: Development of Novel Biomarkers in Cancer: Detection of 
Circulating mir-141 as a Potential Prognostic Marker for Prostate Cancer 
  
Thesis Examination Committee: 
 Examination Committee Chair, Ronald K. Gary, Ph.D. 
 Examination Committee Co-Chair, David C. Ward, Ph.D. 
 Committee Member, Bryan L. Spangelo, Ph.D. 
 Graduate Faculty Representative, Eduardo A. Robleto, Ph.D. 
